CVS Obesity Drug Deal with Eli Lilly: What It Means for GLP-1 Drug Pricing and Insurance Coverage
CVS Health has struck a new preferred formulary deal with Eli Lilly, placing Zepbound on equal footing with Novo Nordisk's Wegovy in obesity drug coverage. This shift could meaningfully affect what patients pay out of pocket for GLP-1 medications, how insurers structure their tiers, and which drug your plan actually covers.
Understanding the CVS–Eli Lilly Deal and Why It Matters
For months, Novo Nordisk held a distinct advantage in pharmacy benefit manager (PBM) negotiations — Wegovy was the preferred branded GLP-1 obesity drug on many CVS Caremark formularies, while Eli Lilly's Zepbound (tirzepatide) was either non-preferred or required additional prior authorization steps. That dynamic has now shifted.
CVS Health, which operates one of the largest PBM businesses in the United States through CVS Caremark, has reached an agreement that gives Zepbound preferred formulary status alongside Wegovy. In practical terms, this means both drugs now sit at the same tier for many plan sponsors — a dramatic change from the previous arrangement that effectively steered patients toward one manufacturer over the other.
What "Preferred Formulary Status" Actually Means for Patients
When a drug receives preferred formulary placement, your insurance plan typically assigns it a lower cost-sharing tier. That usually translates to a lower copay or coinsurance rate compared to non-preferred alternatives. For a drug like Zepbound, which carries a list price around $1,060 per month for the highest dose, even a single tier improvement in formulary placement can save patients hundreds of dollars monthly.
Preferred status also tends to reduce prior authorization friction. Plans often require extensive documentation — proof of a BMI above 30, comorbid conditions, failed attempts with other weight-loss interventions — before approving GLP-1 drugs at all. When a drug is preferred, those hurdles can be somewhat lower, though they rarely disappear entirely.
How This Deal Changes the Competitive Landscape Between Lilly and Novo Nordisk
Before this agreement, Novo Nordisk had successfully negotiated Wegovy into preferred positions across several major PBMs, partly by offering rebates that made the drug more attractive to plan sponsors on a net-cost basis. Eli Lilly has now demonstrated it can compete aggressively on that same commercial playing field.
The significance here goes beyond one PBM contract. CVS Caremark manages pharmacy benefits for tens of millions of Americans. When a formulary change happens at that scale, it can shift prescription volumes, affect manufacturer revenue projections, and — most importantly for patients — change what real people actually pay at the pharmacy counter.
Rebates, Net Pricing, and What Patients Don't Always See
One complexity worth understanding is that formulary negotiations often hinge on rebates paid from manufacturers back to PBMs and plan sponsors. A drug's list price may be $1,000 per month, but the net price — after rebates — can be significantly lower. The problem is that patients are frequently charged based on the list price, not the net price, especially if they haven't met their deductible.
This is one reason why tools like the GLP-1 cost calculator can be so useful. Rather than trying to decode rebate structures and tier placements yourself, running the numbers based on your specific plan details gives you a clearer picture of what you'll actually owe.
Implications for GLP-1 Drug Pricing Going Forward
The CVS deal signals something broader: the obesity drug market has matured to the point where two well-funded competitors are fighting aggressively for market share through the PBM channel. That competition, in theory, should benefit patients — but whether lower net prices translate to lower patient costs depends heavily on how individual plan sponsors pass those savings through.
Will Prices Actually Drop for Patients?
This is the critical question. Historical patterns in the pharmaceutical industry suggest that increased formulary competition can reduce what plans pay on a net basis, but those savings don't automatically flow to members at the pharmacy counter. Much depends on how an employer or insurer has structured their benefit design.
Some self-insured employers, for example, work directly with PBMs to customize their formularies and may choose to lower member cost-sharing when they're receiving better rebates. Large commercial plans may do the same. However, plans operating on a standard template may not pass savings through at all — at least not immediately.
According to CMS data on prescription drug spending trends, specialty drugs including newer obesity medications have been among the fastest-growing cost categories for both public and private payers. You can review CMS's National Health Expenditure data directly at cms.gov to understand the broader context of drug spending in the U.S.
Manufacturer Savings Programs as a Stopgap
Both Eli Lilly and Novo Nordisk offer savings card programs for commercially insured patients. Lilly's savings program for Zepbound, at the time of writing, can reduce costs to as low as $25 per month for eligible patients, though income limits and insurance type restrictions apply. These programs exist precisely because formulary coverage remains inconsistent — they're a manufacturer's way of smoothing access while broader insurance coverage catches up.
If you're trying to figure out whether a savings card changes your effective cost, the GLP-1 drug cost calculator can help you model scenarios with and without those discounts applied.
Medicare and Medicaid: A Different Coverage Picture
It's worth noting that the CVS–Lilly deal primarily affects commercial insurance markets. Medicare and Medicaid coverage for obesity drugs operates under different rules entirely, and the landscape there has been changing rapidly.
Medicare Part D plans were historically prohibited from covering drugs used primarily for weight loss under the Exclusion for Weight Loss provisions. The Treat and Reduce Obesity Act has been proposed repeatedly in Congress to change this, though it has not yet passed into law as of this writing. Some Medicare plans do cover GLP-1 drugs when prescribed for Type 2 diabetes management rather than obesity specifically — tirzepatide is approved as Mounjaro for diabetes, and semaglutide is available as Ozempic for diabetes, creating a coverage pathway that doesn't exist when the same compounds are prescribed under their obesity-specific brand names.
For Medicaid, coverage varies significantly by state. CMS has provided guidance to states that wish to add obesity drug coverage, but participation is not mandatory. Patients on Medicaid should check their specific state plan or speak with a benefits coordinator to understand current coverage. You can find additional Medicaid prescription drug coverage information at cms.gov's Medicaid drug coverage page.
What Patients Should Do Right Now
If you're currently taking or considering Zepbound or Wegovy, the CVS–Lilly deal is worth paying attention to — but don't assume it automatically changes your costs. Here's a practical framework for navigating this moment.
Step One: Check Your Formulary Directly
Formulary changes don't always take effect immediately, and not all plan sponsors using CVS Caremark will adopt the same formulary structure. Log into your insurance plan's member portal or call the number on your insurance card to ask specifically about the current tier status of Zepbound versus Wegovy on your plan. Ask about prior authorization requirements and whether any restrictions changed recently.
Step Two: Run the Numbers Before Switching
If your plan now covers Zepbound at a lower cost-sharing tier than Wegovy, switching might make financial sense — but only after accounting for the full picture. Consider whether you've had success with your current medication, whether your prescriber is comfortable with both options, and what your remaining deductible situation looks like for the year. Use the GLP-1 cost calculator to compare estimated out-of-pocket costs across both drugs under your specific plan parameters.
Step Three: Keep Watching for Open Enrollment Changes
The real opportunity to benefit from competitive GLP-1 pricing may come during your employer's next open enrollment period. If your employer adjusts its formulary structure in response to better manufacturer rebates, you may see different cost-sharing tiers for these drugs in the plan year ahead. Reviewing the Summary of Benefits and Coverage document for each plan option you're eligible for — with specific attention to specialty drug cost-sharing — is time well spent.
Frequently Asked Questions
Does the CVS–Eli Lilly deal mean Zepbound is now covered by my insurance?
Not necessarily. The deal affects formulary placement within CVS Caremark's managed plans, but coverage ultimately depends on which plan your employer or insurer has adopted, and whether that plan has implemented the updated formulary. Contact your insurance provider directly to confirm Zepbound's current status on your specific plan.
Will this competition between Lilly and Novo Nordisk lower list prices for GLP-1 drugs?
Formulary competition typically drives down net prices through rebates rather than lowering published list prices. List prices for Wegovy and Zepbound remain well above $1,000 per month at standard doses. Whether patients see any reduction in out-of-pocket costs depends on how plan sponsors choose to structure member cost-sharing in response to improved rebates.
How do I figure out which GLP-1 drug is cheapest under my insurance?
The most reliable approach is to check your plan's current formulary for the tier placement of each drug, confirm whether your deductible has been met, and factor in any applicable manufacturer savings programs. A GLP-1 cost calculator that incorporates your plan type, deductible status, and tier information will give you a personalized estimate more quickly than trying to interpret an explanation of benefits document on your own.
What if I'm on Medicare and want to access Zepbound for obesity treatment?
Medicare Part D currently excludes coverage for drugs prescribed primarily for weight loss, which affects Zepbound when prescribed under its obesity indication. Some Medicare plans cover tirzepatide as Mounjaro when prescribed for Type 2 diabetes. Legislative changes could expand coverage in the future, so it's worth monitoring updates from CMS and speaking with your prescriber about how your diagnosis is being documented.